22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim CEO...
18:13 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Replimune prices $100.5M IPO in middle of range

Replimune Group Inc. (NASDAQ:REPL) raised $100.5 million late July 19 through the sale of 6.7 million shares at $15 in an IPO underwritten by J.P. Morgan, Leerink and BMO Capital Markets. The price, which was...
17:13 , Jul 20, 2018 |  BC Week In Review  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
16:38 , Jul 20, 2018 |  BC Week In Review  |  Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on July 17 proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. CanSino said in its prospectus that...
02:48 , Jul 20, 2018 |  BC Extra  |  Financial News

Replimune ticks up after pricing $100.5M IPO

Replimune Group Inc. (NASDAQ:REPL) gained $0.16 to $15.16 on Friday after it raised $100.5 million through the sale of 6.7 million shares at $15 in an IPO. Underwriters are J.P. Morgan, Leerink and BMO Capital...
10:02 , Jul 18, 2018 |  BC Extra  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
22:18 , Jul 17, 2018 |  BC Extra  |  Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on Tuesday proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. The news comes as multiple media...
22:02 , Jul 17, 2018 |  BC Extra  |  Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on Tuesday proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. The news comes as multiple media...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Company News

Regulus reducing headcount by 60%

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome to save cash. In May 2017, the company reduced its headcount by...